NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

AMGN

AMGEN Inc

Jul 03 • 04:00PM ET

298.24

Dollar change +1.39
Percentage change 0.47	%

Healthcare • Drug Manufacturers - General • USA • NASD

Peers: BIIB GILD REGN VRTX BMY MRNA ILMN PFE NBIX ABBV

| Held by: VTI VOO QQQ SCHD SPY IVV DIA VTV XLV VIG

Scroll to Statements

Index	DJIA, NDX, S&P 500	P/E	27.22	EPS (ttm)	10.95	Insider Own	0.22%	Shs Outstand	537.70M	Perf Week	6.85%
Market Cap	160.37B	Forward P/E	13.86	EPS next Y	21.52	Insider Trans	-6.53%	Shs Float	536.51M	Perf Month	2.99%
Enterprise Value	208.94B	PEG	6.16	EPS next Q	5.23	Inst Own	81.09%	Short Float	2.47%	Perf Quarter	-2.44%
Income	5.93B	P/S	4.73	EPS this Y	5.17%	Inst Trans	3.00%	Short Ratio	4.32	Perf Half Y	15.02%
Sales	33.93B	P/B	25.84	EPS next Y	3.12%	ROA	6.51%	Short Interest	13.27M	Perf YTD	14.43%
Book/sh	11.54	P/C	18.20	EPS next 5Y	4.42%	ROE	105.67%	52W High	346.85 -14.01%	Perf Year	-4.11%
Cash/sh	16.38	P/FCF	14.69	EPS past 3/5Y	-9.75% -10.10%	ROIC	9.85%	52W Low	253.30 17.74%	Perf 3Y	22.48%
Dividend Est.	9.65 (3.23%)	EV/EBITDA	14.42	Sales past 3/5Y	8.54% 7.40%	Gross Margin	67.43%	Volatility	2.55% 2.55%	Perf 5Y	28.09%
Dividend TTM	9.26 (3.10%)	EV/Sales	6.16	EPS Y/Y TTM	56.99%	Oper. Margin	26.26%	ATR (14)	7.53	Perf 10Y	87.86%
Dividend Ex-Date	May 16, 2025	Quick Ratio	0.88	Sales Y/Y TTM	15.59%	Profit Margin	17.49%	RSI (14)	61.97	Recom	2.21
Dividend Gr. 3/5Y	8.53% 9.18%	Current Ratio	1.17	EPS Q/Q	1616.98%	SMA20	3.54%	Beta	0.47	Target Price	316.39
Payout	119.05%	Debt/Eq	9.24	Sales Q/Q	9.42%	SMA50	5.73%	Rel Volume	0.49	Prev Close	296.85
Employees	28000	LT Debt/Eq	8.70	Earnings	May 01 AMC	SMA200	1.49%	Avg Volume	3.07M	Price	298.24
IPO	Jun 17, 1983	Option/Short	Yes / Yes	EPS/Sales Surpr.	14.76% 1.14%	Trades		Volume	1,518,514	Change	0.47%

Date	Action	Analyst	Rating Change	Price Target Change
May-20-25	Resumed	Guggenheim	Neutral	$288
Apr-22-25	Resumed	Cantor Fitzgerald	Neutral	$305
Dec-10-24	Resumed	BofA Securities	Underperform	$256
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-14-24	Initiated	Citigroup	Neutral	$335
Oct-17-24	Initiated	Bernstein	Outperform	$380
Oct-14-24	Downgrade	Truist	Buy → Hold	$320 → $333
Sep-27-24	Initiated	Cantor Fitzgerald	Overweight	$405
Aug-07-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$320 → $335
May-03-24	Upgrade	William Blair	Mkt Perform → Outperform
May-03-24	Upgrade	Barclays	Underweight → Equal Weight	$230 → $300
Mar-28-24	Resumed	Raymond James	Mkt Perform
Feb-07-24	Downgrade	Leerink Partners	Outperform → Market Perform	$324 → $318
Dec-21-23	Upgrade	Daiwa Securities	Neutral → Buy	$264 → $320
Dec-19-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$286 → $326
Dec-12-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$256 → $300
Nov-09-23	Initiated	Deutsche Bank	Hold	$240
Nov-02-23	Upgrade	Truist	Hold → Buy	$260 → $320
Oct-20-23	Resumed	JP Morgan	Neutral	$265 → $270
Oct-17-23	Resumed	Morgan Stanley	Equal-Weight	$300

Show Previous Ratings

Today 03:35AM	Amgen (AMGN) Announces Positive Results for Phase 3 Study of Bemarituzumab (Insider Monkey)
Jul-04-25 03:22AM	Piper Sandler Reaffirms Buy on Amgen Amid MariTide Tolerability Update (Insider Monkey)
01:01AM	Lilly and Novo Are the Kings of Weight-Loss Drugs. The Companies Coming for Their Crowns. (Barrons.com)
Jul-03-25 06:36AM	PharmaVentures Appoints Samara Ferguson as Vice President to Lead Pricing and Market Access Team (PR Newswire)
02:47AM	Amgen (AMGN) Announces Full Results from Part 1 of the Phase 2 study of MariTide (Insider Monkey)
07:31PM	Loading…
Jul-02-25 07:31PM	Analyst Report: Amgen Inc. (Morningstar Research)
05:50PM	Amgen (AMGN) Outperforms Broader Market: What You Need to Know (Zacks)
01:34PM	Final Trades: Amgen, Caterpillar, Honeywell and Freeport-McMoran (CNBC TV)
09:07AM	Does J&J's Innovative Medicine Unit Hold the Key to Q2 Sales Growth? (Zacks)
09:00AM	mAbxience Announces European Commission Approval of Denosumab Biosimilars (PR Newswire)
Jul-01-25 09:14PM	This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk (Motley Fool)
06:55PM	Why Amgen Stock Popped by 4% Today (Motley Fool)
06:09PM	Trading Rotation Kicks Off 2nd Half of 2025 (Zacks)
12:11PM	Stock Market Today: Dow jumps; S&P 500 and Nasdaq slip (TheStreet)
09:00AM	Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know (Zacks)
05:32AM	Loading…
05:32AM	Amgen and Zai Labs trial of gastric cancer therapy meets primary endpoint (Clinical Trials Arena)
Jun-30-25 04:05PM	Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? (Investor's Business Daily)
09:00AM	AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER (PR Newswire)
06:20AM	Should You Invest in the VanEck Biotech ETF (BBH)? (Zacks)
05:05AM	2 Dividend Stocks to Buy on the Dip and Hold Forever (Motley Fool)
Jun-28-25 12:20PM	Jim Cramer Says That Amgen's Stock "Did Not Deserve to Get Hit This Hard" (Insider Monkey)
Jun-27-25 11:10AM	NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now? (Zacks)
10:10AM	Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed? (Zacks)
09:45AM	Here's Why Amgen (AMGN) is a Strong Growth Stock (Zacks)
09:35AM	Cancer Vaccine (Preventative, Therapeutic) Market Research 2025 with Analyst Recommendations-Leveraging AI and Bioinformatics for Precision Development / Pursue Fast-Track and Orphan Drug Designations (GlobeNewswire)
Jun-26-25 11:12AM	VKTX Initiates Phase 3 Study on Obesity Candidate VK2735 (Zacks)
04:02AM	5 Insightful Analyst Questions From Amgen's Q1 Earnings Call (StockStory)
Jun-25-25 05:50PM	Amgen (AMGN) Stock Moves 1.03%: What You Should Know (Zacks)
09:40AM	Here's Why Amgen (AMGN) is a Strong Value Stock (Zacks)
Jun-24-25 02:07PM	Amgen (AMGN) Falls 5.8% as Novo Nordisk Hammers Its Weight Loss Drug Trial (Insider Monkey)
11:49AM	Loading…
11:49AM	Hims & Hers Strengthens Its Footprint in Consumer-Driven Obesity Care (Zacks)
11:00AM	Analyst Report: Amgen Inc. (Morningstar Research)
07:52AM	New Amgen obesity drug data disappoint Wall Street (BioPharma Dive)
Jun-23-25 09:57PM	Analyst Report: Amgen Inc. (Morningstar Research) -5.84%
06:00PM	Amgen (AMGN) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
04:53PM	S&P 500 Gains & Losses Today: Robotaxi Drives Tesla Surge, Supermicro Stock Drops (Investopedia)
04:15PM	Amgen Shares Fall on Weight-Loss Drug Tummy Troubles (Barrons.com)
03:49PM	Amgen stock slips, weight-loss drug moves to phase 3 trial (Yahoo Finance Video)
02:31PM	RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS (PR Newswire)
02:30PM	Amgen gears up for phase 3 trial of monthly weight-loss drug MariTide amid mixed investor sentiment (Yahoo Finance)
02:30PM	Amgen Expands Development Plans For Highly Anticipated Obesity Drug (Investor's Business Daily)
12:51PM	Stock Market Today: Dow Jones Reverses, Tesla Surges; These Defense Stocks Gain After Iran Attack (Live Coverage) (Investor's Business Daily)
09:22AM	J&J Adds More Than $15B in Six Months: How to Play JNJ Stock? (Zacks)
Jun-20-25 09:00AM	Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Jun-18-25 10:49PM	Celltrion opens new UK headquarters in Uxbridge, UK (Business Wire)
10:52AM	Can Ozempic, Wegovy Drive Further Growth for NVO in the Obesity Space? (Zacks)
09:00AM	AMGEN'S PHASE 2 MARITIDE DATA TO BE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS (PR Newswire)
Jun-17-25 11:20AM	Amgen Boosts Growth With Strong Q1 Results and $1.9B Infrastructure Investment (Insider Monkey)
09:33AM	Members of Congress Are Pouring Millions Into These 7 Surprising Stocks (Motley Fool)
Jun-16-25 11:13PM	Amgen's Strong Cash Flow Supports Reliable Dividend Payments (Insider Monkey)
12:35PM	Novo Nordisk Stock Rises 6% in a Week: What Should Investors Do? (Zacks)
09:00AM	Can J&J's Innovative Medicines Unit Sustain Growth Amid Stelara LOE? (Zacks)
06:36AM	EHA 2025: Regenerons Lynozyfic with Amgens Kyprolis combo emerges for R/R MM (Pharmaceutical Technology)
Jun-15-25 05:38AM	Amgen Announces Significant Survival Benefit for Lung Cancer Drug IMDELLTRA in Phase 3 Trial (Insider Monkey)
Jun-13-25 10:41AM	Lilly Moves Past 50-Day Average: Should You Buy the Stock Now? (Zacks)
09:47AM	BMY Focuses on Label Expansion of Drugs: Will This Revive Growth? (Zacks)
09:00AM	AMGEN AND FOOTBALL LEGEND BARRY SANDERS HIGHLIGHT DANGERS OF BAD CHOLESTEROL IN NEW DOCUMENTARY (PR Newswire)
Jun-12-25 05:50PM	Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider (Zacks)
Jun-11-25 09:50AM	Here's Why Amgen (AMGN) is a Strong Momentum Stock (Zacks)
09:38AM	Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space? (Zacks)
Jun-10-25 08:24PM	Analyst Report: Amgen Inc. (Morningstar Research)
09:45AM	Why Amgen (AMGN) is a Top Growth Stock for the Long-Term (Zacks)
Jun-09-25 11:15PM	Flex joins MIT's 'New Manufacturing' initiative, aims to reinvent US industry with AI and global sustainability labs (DigiTimes)
11:08AM	Merck Pill Lowers Cholesterol Levels. By How Much Is the Critical Point. (Barrons.com)
09:40AM	Why Amgen (AMGN) is a Top Value Stock for the Long-Term (Zacks)
09:00AM	Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
06:20AM	Should You Invest in the iShares Biotechnology ETF (IBB)? (Zacks)
Jun-06-25 01:31PM	The Next Look At Amgen's Obesity Drug Is Coming. Here's What Investors Are Watching. (Investor's Business Daily)
06:45AM	2 Dividend Growth Stocks to Buy and Hold Forever (Motley Fool)
Jun-05-25 04:01PM	AMGEN TO PRESENT AT GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE (PR Newswire)
01:58PM	BetterInvesting Magazine Update on The Walt Disney Co. (NYSE: DIS) (PR Newswire)
11:28AM	RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar (Zacks)
Jun-04-25 10:31AM	Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks (Zacks)
05:52AM	ASCO 2025: DeLLphi-304 helps Amgen to pave the way for BiTEs in solid cancers (Clinical Trials Arena)
Jun-03-25 09:43AM	Amgen's Imdelltra Cuts Lung Cancer Death Risk by 40% in Phase III (Zacks)
Jun-02-25 01:38PM	ASCO25: Amgens Nplate proves effective in GI cancer-linked thrombocytopaenia (Clinical Trials Arena)
09:10AM	3 Top Dividend Stocks to Maximize Your Retirement Income (Zacks)
08:04AM	IMDELLTRA SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS (PR Newswire)
07:00AM	3 No-Brainer Healthcare Stocks to Buy in June (Motley Fool)
May-30-25 04:01PM	AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE (PR Newswire)
May-29-25 04:45AM	Is Amgen Stock a Buy? (Motley Fool)
May-27-25 10:18PM	BetterInvesting Magazine Update on Stride Inc. (NYSE: LRN) and Amgen Inc. (NASDAQ: AMGN) (PR Newswire)
11:19AM	TEVA Stock Up Around 13% in a Month: Buy, Sell or Hold the Stock? (Zacks)
09:00AM	Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know (Zacks)
May-26-25 09:10AM	How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks (Zacks)
May-24-25 07:15AM	The Smartest High-Yielding Dividend Stocks in the Nasdaq Composite Index to Buy With $1,500 Right Now (Motley Fool)
04:11AM	U.S. Pharmaceutical Imports Might Soon Face Tariffs: 3 Stocks That Could Tumble as a Result (Motley Fool)
May-23-25 08:42AM	The Zacks Analyst Blog Highlights Eli Lilly, GE Aerospace and Amgen (Zacks)
May-22-25 04:34PM	Top Analyst Reports for Eli Lilly, GE Aerospace & Amgen (Zacks)
11:05AM	Better Weight Loss Stock: Amgen or Viking Therapeutics? (Motley Fool)
10:06AM	Sanofi Inks A $470 Million Alzheimer's Deal, Sending This Dollar Stock Flying (Investor's Business Daily)
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
09:07AM	JNJ Down 6% in 3 Months: How to Play the Stock Amid Various Challenges (Zacks)
May-21-25 08:50AM	AMGN Down 10% in 3 Months: How to Play the Stock as Tariff Woes Linger (Zacks)
07:03AM	Viridian Therapeutics veligrotug shows durability in Phase III TED trial (Clinical Trials Arena)
May-19-25 01:29PM	Amgen vs Bristol Myers: Which Biotech Giant Has Better Prospects? (Zacks)
10:15AM	Novo Nordisk Shares Dip 3% on Sudden CEO Transition Announcement (Zacks)
09:10AM	Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks (Zacks)
12:39AM	2 Safe-and-Steady Stocks Worth Your Attention and 1 to Avoid (StockStory)
May-16-25 04:01PM	AMGEN TO PRESENT AT THE 2025 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE (PR Newswire)

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Khosla Rachna	SVP, Business Development	Jun 05 '25	Sale	289.68	1,500	434,520	8,162	Jun 06 07:49 PM
Khosla Rachna	Officer	Jun 05 '25	Proposed Sale	290.00	1,500	435,000		Jun 05 12:24 PM
Busch Matthew C.	VP, Finance & CAO	May 02 '25	Sale	279.69	1,000	279,690	4,034	May 06 08:07 PM
Busch Matthew C.	Officer	May 02 '25	Proposed Sale	281.44	1,000	281,440		May 02 02:37 PM
Santos Esteban	EVP, Operations	Feb 19 '25	Option Exercise	156.35	8,711	1,361,965	80,257	Feb 21 08:07 PM
Santos Esteban	EVP, Operations	Feb 19 '25	Sale	292.84	8,711	2,550,903	71,546	Feb 21 08:07 PM
REESE DAVID M	EVP & Chief Technology Officer	Feb 19 '25	Option Exercise	156.35	8,711	1,361,965	70,858	Feb 21 08:06 PM
REESE DAVID M	EVP & Chief Technology Officer	Feb 21 '25	Sale	304.44	25,225	7,679,524	36,922	Feb 21 08:06 PM
REESE DAVID M	EVP & Chief Technology Officer	Feb 19 '25	Sale	293.22	8,711	2,554,224	62,147	Feb 21 08:06 PM
DAVID M REESE & JOAN I CHUCO-T	Officer	Feb 21 '25	Proposed Sale	304.44	25,225	7,679,524		Feb 21 04:27 PM
Miller Derek	SVP, Human Resources	Feb 19 '25	Option Exercise	156.35	1,524	238,277	10,068	Feb 20 08:59 PM
Miller Derek	SVP, Human Resources	Feb 19 '25	Sale	293.74	1,524	447,655	8,544	Feb 20 08:59 PM
Miller Derek	SVP, Human Resources	Feb 18 '25	Sale	292.56	500	146,279	8,544	Feb 20 08:59 PM
DEREK MILLER	Officer	Feb 19 '25	Proposed Sale	293.74	1,524	447,655		Feb 19 04:18 PM
DAVID REESE	Officer	Feb 19 '25	Proposed Sale	293.22	8,711	2,554,224		Feb 19 04:14 PM
Santos Esteban	Affiliate	Feb 19 '25	Proposed Sale	292.11	8,711	2,544,570		Feb 19 02:25 PM
DEREK MILLER	Officer	Feb 18 '25	Proposed Sale	292.56	500	146,279		Feb 18 04:10 PM
Gordon Murdo	EVP, Global Commercial Ops	Feb 11 '25	Sale	294.79	8,771	2,585,644	44,186	Feb 13 09:02 PM
Gordon Murdo	Officer	Feb 11 '25	Proposed Sale	295.30	8,771	2,590,076		Feb 11 03:01 PM
Graham Jonathan P	EVP & Gen. Counsel & Secy.	Feb 07 '25	Option Exercise	156.35	25,045	3,915,786	54,032	Feb 10 09:52 PM
Graham Jonathan P	EVP & Gen. Counsel & Secy.	Feb 07 '25	Sale	293.12	25,045	7,341,123	28,987	Feb 10 09:52 PM
Graham Jonathan P	Officer	Feb 07 '25	Proposed Sale	292.94	25,045	7,336,682		Feb 07 03:05 PM
Grygiel Nancy A.	SVP & CCO	Feb 05 '25	Sale	304.47	1,589	483,808	7,210	Feb 06 08:54 PM
Grygiel Nancy A.	Officer	Feb 05 '25	Proposed Sale	304.47	1,589	483,800		Feb 05 12:53 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AMGN

AMGEN Inc

Upgrade your FINVIZ experience